Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BTAI

BTAI - Bioxcel Therapeutics Inc Stock Price, Fair Value and News

$1.67-0.10 (-5.65%)
Market Closed

2/100

BTAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

2/100

BTAI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.46

Target 3M

$1.64

Target 6M

$1.55

BTAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BTAI Price Action

Last 7 days

-9.2%

Last 30 days

7.0%

Last 90 days

-17.3%

Trailing 12 Months

-69.6%

BTAI RSI Chart

BTAI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BTAI Valuation

Market Cap

36.5M

Price/Earnings (Trailing)

-0.54

Price/Sales (Trailing)

48.57

Price/Free Cashflow

-0.64

BTAI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.46

Target 3M

$1.64

Target 6M

$1.55

BTAI Fundamentals

BTAI Revenue

Revenue (TTM)

752.0K

Rev. Growth (Yr)

-54.21%

Rev. Growth (Qtr)

-18.33%

BTAI Earnings

Earnings (TTM)

-68.2M

Earnings Growth (Yr)

-126.45%

Earnings Growth (Qtr)

-61.1%

BTAI Profitability

Return on Equity

76.71%

Return on Assets

-152.28%

Free Cashflow Yield

-155.72%

BTAI Investor Care

Shares Dilution (1Y)

718.54%

Diluted EPS (TTM)

-8.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.9M868.0K752.0K0
20241.8M2.4M2.3M2.3M
2023626.3K877.5K1.1M1.4M
2022000375.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Bioxcel Therapeutics Inc

BTAI
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
 CEO
 WEBSITEbioxceltherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES183

Bioxcel Therapeutics Inc Frequently Asked Questions

BTAI is the stock ticker symbol of Bioxcel Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bioxcel Therapeutics Inc is 36.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BTAI's fair value in chart for subscribers.

The fair value guage provides a quick view whether BTAI is over valued or under valued. Whether Bioxcel Therapeutics Inc is cheap or expensive depends on the assumptions which impact Bioxcel Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTAI.

As of Wed Jan 28 2026, BTAI's PE ratio (Price to Earnings) is -0.54 and Price to Sales (PS) ratio is 48.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTAI PE ratio will change depending on the future growth rate expectations of investors.